ArticleNature communications2021
Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum.
Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
90 citing papers in PubMed, 1 synthesis or guideline pooled it, 131 citations in OpenAlex.
- Potency of BNT162b2 and mRNA-1273 vaccine-induced neutralizing antibodies against severe acute respiratory syndrome-CoV-2 variants of concern: A systematic review of in vitro studies.Reviews in medical virology · 2022Pooled it
- Disulfide bonds stabilize the SARS-CoV-2 RBD and preserve binding to ACE2 following thermal denaturation.Bioscience reports · 2026Article
- Dirty mice better recapitulate key features of mRNA vaccine immunogenicity observed in humans.mBio · 2026Article
- Dirty mice better recapitulate key features of mRNA vaccine immunogenicity observed in humans.bioRxiv : the preprint server for biology · 2026Article
- A Nanobody-Based Lateral Flow Assay for Point-of-Care Diagnostics.Biosensors · 2026Article
- Efficacy and safety of a novel multivalent mRNA vaccine against SARS-CoV-2 in experimental animals.Scientific reports · 2025Article
- Multi-Omic Profiling Identifies Conserved Metabolic Pathways Critical for SARS-CoV-2 Variants Infection.bioRxiv : the preprint server for biology · 2025Article
- Immune imprinting and vaccine interval determine antibody responses to monovalent XBB.1.5 COVID-19 vaccination.Communications medicine · 2025Article
- SARS-CoV-2 evolution on a dynamic immune landscape.Nature · 2025Article
- Article
- Evaluating the Quality of Studies Assessing COVID-19 Vaccine Neutralizing Antibody Immunogenicity.Vaccines · 2024Review
- Booster Vaccination with BNT162b2 Improves Cellular and Humoral Immune Response in the Pediatric Population Immunized with CoronaVac.Vaccines · 2024Article
- Designed mosaic nanoparticles enhance cross-reactive immune responses in mice.bioRxiv : the preprint server for biology · 2024Article
- Article
- SARS-CoV-2 vaccination elicits broad and potent antibody effector functions to variants of concern in vulnerable populations.Nature communications · 2023Article
- Article
- Article
- Fc-γR-dependent antibody effector functions are required for vaccine-mediated protection against antigen-shifted variants of SARS-CoV-2.Nature microbiology · 2023Article
- An extended interval between vaccination and infection enhances hybrid immunity against SARS-CoV-2 variants.JCI insight · 2023Article
- Elevated risk of infection with SARS-CoV-2 Beta, Gamma, and Delta variants compared with Alpha variant in vaccinated individuals.Science translational medicine · 2023Article
30 more citing papers are in PubMed but not listed here.
Corrections and comments
- Update of
Authors and funding
19 authors at 4 institutions in 1 country.
Funding
Abstract
SARS-CoV-2 and its variants continue to infect hundreds of thousands every day despite the rollout of effective vaccines. Therefore, it is essential to understand the levels of protection that these vaccines provide in the face of emerging variants. Here, we report two demographically balanced cohorts of BNT162b2 vaccine recipients and COVID-19 patients, from which we evaluate neutralizing antibody titers against SARS-CoV-2 as well as the B.1.1.7 (alpha) and B.1.351 (beta) variants. We show that both B.1.1.7 and B.1.351 are less well neutralized by serum from vaccinated individuals, and that B.1.351, but not B.1.1.7, is less well neutralized by convalescent serum. We also find that the levels of variant-specific anti-spike antibodies are proportional to neutralizing activities. Together, our results demonstrate the escape of the emerging SARS-CoV-2 variants from neutralization by serum antibodies, which may lead to reduced protection from re-infection or increased risk of vaccine breakthrough.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.